Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 396

Similar articles for PubMed (Select 18986296)

1.

Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.

Tillotson GS, Echols RM.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S237-40. doi: 10.1086/591408. Review.

2.

Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.

Echols RM, Tillotson GS, Song JX, Tosiello RL.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S166-75. doi: 10.1086/591399. Review.

3.

Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.

Gilbert DN.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S121-2. doi: 10.1086/591391.

4.

Overview of recent studies of community-acquired pneumonia.

Higgins K, Singer M, Valappil T, Nambiar S, Lin D, Cox E.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S150-6. doi: 10.1086/591397. Review.

5.

Clinical and microbiological end points in the treatment of pneumonia.

Musher DM.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S207-9. doi: 10.1086/591406. Review.

6.
7.
8.

Is it possible to blind a trial for community-acquired pneumonia?

Boucher HW.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S210-5. doi: 10.1086/591428. Review.

9.

Effective treatment strategies for paediatric community-acquired pneumonia.

Atkinson M, Yanney M, Stephenson T, Smyth A.

Expert Opin Pharmacother. 2007 Jun;8(8):1091-101. Review.

PMID:
17516873
10.
11.

Adjunctive therapy in community-acquired pneumonia.

Wunderink RG.

Semin Respir Crit Care Med. 2009 Apr;30(2):146-53. doi: 10.1055/s-0029-1202933. Epub 2009 Mar 18. Review.

PMID:
19296414
12.

Therapies in development for community-acquired pneumonia.

Blasi F, Braga P, Cazzola M, Cosentini R, Tarsia P.

Expert Opin Investig Drugs. 2002 Apr;11(4):545-52. Review.

PMID:
11922862
14.

New antimicrobial molecules and new antibiotic strategies.

Rodríguez de Castro F, Naranjo OR, Marco JA, Violán JS.

Semin Respir Crit Care Med. 2009 Apr;30(2):161-71. doi: 10.1055/s-0029-1202935. Epub 2009 Mar 18. Review.

PMID:
19296416
15.

Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.

Singer M, Nambiar S, Valappil T, Higgins K, Gitterman S.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S216-24. doi: 10.1086/591407. Review.

16.

Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.

Barriere SL.

Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S4-9. doi: 10.1086/653033. Review. Erratum in: Clin Infect Dis. 2010 Nov 1;51(9):1114.

17.

Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?

Ludlam HA, Enoch DA.

Int J Antimicrob Agents. 2008 Aug;32(2):101-5. doi: 10.1016/j.ijantimicag.2008.02.003. Epub 2008 Jun 20. Review.

PMID:
18571380
18.

Clinical perspectives on the management of community-acquired pneumonia.

Garau J.

Diagn Microbiol Infect Dis. 1996 Aug;25(4):205-11.

PMID:
8937846
19.

Efficacy as an important facet of "safety" in clinical trials: how can we do our best for our patients?

Talbot GH.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S180-5. doi: 10.1086/591401. Review.

20.

Executive summary: workshop on issues in the design and conduct of clinical trials of antibacterial drugs in the treatment of community-acquired pneumonia.

Spellberg B, Fleming TR, Gilbert DN.

Clin Infect Dis. 2008 Dec 1;47 Suppl 3:S105-7. doi: 10.1086/591389. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk